Dual selective PI3 delta and gamma kinase inhibitors
AssigneeRhizen Pharmaceuticals SA
InventorsSwaroop K. V. S. Vakkalanka, Prashant K. Bhavar, Srikant Viswanadha, Govindarajulu Babu
Life of this patent
Estimating the term…
Abstract
The present invention relates to dual delta (δ) and gamma (γ) PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of Pi3K kinase mediated diseases or disorders with them.
Claims32
A composition comprising (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one or a pharmaceutically acceptable salt thereof, wherein the composition is substantially free of (R)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one and pharmaceutically acceptable salts thereof.
A composition comprising (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one, wherein the composition is substantially free of (R)-2-(1-(9H-purin-6-ylamino)prop yl)-3-(3-fluorophenyl)-4H-chromen-4-one.
A composition comprising (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one or a pharmaceutically acceptable salt thereof, wherein the composition has an enantiomeric excess greater than about 90% relative to (R)-2-(1-(9H-purin-6-ylamino)propyI)-3-(3-fluorophenyl)-4H-chromen-4-one.
A composition comprising (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one, wherein the composition has an enantiomeric excess greater than about 90% relative to (R)-2-(1-(9H-purin-6-ylamino)propyI)-3-(3-fluorophenyl)-4H-chromen-4-one %.
A pharmaceutical composition comprising (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier, wherein the composition is substantially free of (R)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one and pharmaceutically acceptable salts thereof.
A pharmaceutical composition comprising (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one and at least one pharmaceutically acceptable carrier, wherein the composition is substantially free of (R)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one.
A pharmaceutical composition comprising (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier, wherein the composition has an enantiomeric excess greater than about 90% relative to (R)-2-(1-(9H-purin-6-ylamino)propyI)-3-(3-fluorophenyl)-4H-chromen-4-one.
A pharmaceutical composition comprising (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one and at least one pharmaceutically acceptable carrier, wherein the composition has an enantiomeric excess greater than about 90% relative to (R)-2-(1-(9H-purin-6-ylamino)propyI)-3-(3-fluorophenyl)-4H-chromen-4-one.
Dependencies are inferred from the claim text.